▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2804 by analyst upside · 2026-11-13
CTKB
Cytek Biosciences, Inc.
Healthcare · Market Cap $722M · P/E 0x
ANALYST PRICE TARGET
+17.8%
implied upside to consensus target
Current Price $5.52
Consensus Target $6.5
Bull Target $7.5
Bear Target $5.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
1
Hold
1
Sell
0
52-Week Low $3.31
52-Week High $6.33
YTD Return +12.2%
FUNDAMENTALS
Market Cap $722M
P/E Ratio (TTM) N/A
Forward P/E 78.9x
EPS (TTM) $-0.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $208M
Profit Margin -39.1%
52-WEEK RANGE
52-Week Low $3.31
52-Week High $6.33
Current Price $5.52
Bear Target $5.0
Bull Target $7.5
● Now $5.52 ● Target $6.5
TRADING DATA
Avg Volume 1.3M
YTD Return +12.2%
Analyst Count 3
Consensus Buy
Upside to Target +17.8%
Last Updated 2026-11-13

ANALYST SUMMARY

Cytek Biosciences, Inc. (CTKB) is currently trading at $5.52 with a Wall Street consensus price target of $6.5, implying potential upside of 17.8% over the next 12 months. 3 analysts currently cover CTKB, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $7.5, while the most cautious has a target of $5.0.

CTKB operates in the Healthcare sector with a market capitalisation of $722M. The stock is up 12.2% year-to-date and is currently trading near the upper end of its 52-week range of $3.31 – $6.33.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

IRWD +27.3%
Ironwood Pharmaceuticals, Inc.
$803M · P/E 5.4x · Buy
INMD +16.2%
InMode Ltd.
$759M · P/E 10.9x · Hold
ABUS +32.8%
Arbutus Biopharma Corporation
$618M · P/E 3.6x · Buy
RIGL +40.9%
Rigel Pharmaceuticals, Inc.
$860M · P/E 2.8x · Hold
BVS +52.9%
Bioventus Inc.
$744M · P/E 13.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CTKB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Stephens & Co. - Reiterated
Overweight → Overweight 2026-05-13 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-01-08 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-11-11 14% win rate (7 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2025-05-28 Building track record
Goldman Sachs - Reiterated
Sell → Sell 2025-05-12 Building track record
Stephens & Co. reit
Overweight → Overweight 2025-03-19 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-03-04 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
11/30
Consensus clarity
21/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →